Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the American Society of Hypertension : JASH

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jash.2014.11.008PMID 25600419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiogenic factors in diagnosis, management, and research in preeclampsia.

  2014cited by this paper
• Strategy for Standardization of Preeclampsia Research Study Design

  2014cited by this paper
• The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies.

  2014cited by this paper
• Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies

  2014cited by this paper
• New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia

  2014cited by this paper
• Maternal Serum Placental Growth Factor Isoforms 1 and 2 at 11-13, 20-24 and 30-34 Weeks' Gestation in Late-Onset Pre-Eclampsia and Small for Gestational Age Neonates

  2014cited by this paper
• Response to Carbillon L et al. letter titled; “The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia”

  2014cited by this paper
• Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population‐based cohort study

  2013cited by this paper
• Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.

  2013cited by this paper
• Circulating Angiogenic Factors and Urinary Prolactin as Predictors of Adverse Outcomes in Women With Preeclampsia

  2013cited by this paper
• Redefining preeclampsia using placenta-derived biomarkers.

  2013cited by this paper
• Clinical characterization and outcomes of preeclampsia with normal angiogenic profile

  2013cited by this paper
• Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy.

  2012cited by this paper
• Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia

  2012cited by this paper
• Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia

  2012cited by this paper
• Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease

  2011cited by this paper
• Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays.

  2011cited by this paper
• Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats.

  2011cited by this paper
• An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia.

  2010cited by this paper
• Pre-eclampsia

  2010cited by this paper
• Technical performance of the first fully automated assays for human soluble fms-like tyrosine kinase 1 and human placental growth factor

  2009cited by this paper
• Pre-eclampsia

  2005cited by this paper
• Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.

  2005cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

  2004cited by this paper
• Antibiotic use in relation to the risk of breast cancer

  2004cited by this paper
• Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

  2003cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) could contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

  2003cited by this paper
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists.

  2002cited by this paper
• Placenta Growth Factor

  2001cited by this paper
• Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

  2001cited by this paper
• Pre-eclampsia

  2000cited by this paper
• Intrauterine growth curves based on ultrasonically estimated foetal weights

  1996cited by this paper
• Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

  1994cited by this paper
• Rare earth cryptates and homogeneous fluoroimmunoassays with human sera.

  1993cited by this paper
• A concordance correlation coefficient to evaluate reproducibility.

  1989cited by this paper
• Statistical methods for assessing agreement between two methods of clinical measurement.

  1986cited by this paper
• AKUFO AND IBARAPA.

  1965cited by this paper

• Short-term preeclampsia prediction: cutoff variations for sFlt-1/PlGF in U.S. Patients with or without hypertensive disorders

  2025cites this paper
• Short-term Preeclampsia Prediction: Cutoff Variations for sFlt-1/PlGF in U.S. Patients with or without Hypertensive Disorders

  2025cites this paper
• Third-Trimester NT-proBNP for Pre-eclampsia Risk Prediction

  2025cites this paper
• Reference Intervals for the ratio of Soluble FMS-like Tyrosine Kinase-1 and Placental Growth Factor in Pregnant and Non-Pregnant Females in Pakistani Population

  2024cites this paper
• Reference Interval of Soluble FMS‑like Tyrosine Kinase‑1 in Non-Pregnant and Pregnant Females: A Novel Biomarker for Pre-eclampsia.

  2023cites this paper
• Applying the concept of uncertainty to the sFlt-1/PlGF cut-offs for diagnosis and prognosis of preeclampsia

  2021cites this paper
• Media Kesehatan Masyarakat Indonesia

  2021cites this paper
• Decision Threshold for Kryptor sFlt‐1/PlGF Ratio in Women With Suspected Preeclampsia: Retrospective Study in a Routine Clinical Setting

  2021cites this paper
• Decision-making based on sFlt-1/PlGF ratios: are immunoassay results interchangeable for diagnosis or prognosis of preeclampsia?

  2020cites this paper
• Blood Pressure and Angiogenic Markers in Pregnancy

  2020cites this paper
• THE ROLE OF PREDICTOR PLACENTAL GROWTH FACTOR, SOLUBLE ENDOGLIN, SOLUBLE-FMS-LIKE-TYROSINE KINASE-1 AND PULSATIL UTERINA ARTERIAL INDEX TO PREDICT THE EARLY ONSET OF PREECLAMPSIA

  2020cites this paper
• University of Southern Denmark Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers an Odense Child Cohort study

  2020cites this paper
• Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.

  2020cites this paper
• Placenta derived factors involved in the pathogenesis of the liver in the syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP): A review.

  2019cites this paper
• The Role of Placental Growth Factor, Soluble Endoglin, and Uterine Artery Diastolic Notch to Predict the Early Onset of Preeclampsia

  2019cites this paper
• Utilidad de los marcadores bioquímicos de preeclampsia

  2019cites this paper
• Aldosterone, Salt, and Potassium Intakes as Predictors of Pregnancy Outcome, Including Preeclampsia.

  2019cites this paper
• Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?

  2019cites this paper
• Role of sFlt-1 and PlGF in the screening of small-for-gestational age neonates during pregnancy: A systematic review

  2019cites this paper
• Preeclampsia features in pregnancy with gestational diabetes mellitus

  2019cites this paper
• The Role of Uterine Artery Diastolic Notch and Uterine Artery Pulsatility Index to Predict the Event of Early Onset Preeclampsia

  2019cites this paper
• Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.

  2018cites this paper
• Soluble fms-like tyrosine kinase-1, placental growth factor and their ratio as a predictor for pre-eclampsia in East Asians.

  2018cites this paper
• Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an Odense Child Cohort study

  2018cites this paper
• Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobas®e 411 Analyser.

  2018cites this paper
• Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at <32 weeks compared with ≥32 weeks.

  2018cites this paper
• Prognostic value of serum soluble FMS-like tyrosine kinase (sFlt-1) levels in pre-eclampsia and eclampsia; a prospective cohort study

  2018cites this paper
• Circulating free soluble fms-like tyrosine kinase-1 during late first trimester in relation with placental volume as a surrogate for trophoblastic production: a physiology study in low-risk cohort

  2017cites this paper
• Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis

  2017influential citation
• Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®.

  2017cites this paper
• Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings.

  2017cites this paper
• Pre-eclampsia: overview on the role of biomarkers in 2016.

  2017cites this paper
• Validation of hospital discharge diagnoses for hypertensive disorders of pregnancy

  2016cites this paper
• Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.

  2016influential citation
• Relevance of Personalized Health Care in Patients with Arterial Hypertension: Where are we now?

  2016cites this paper
• Placenta growth factor som biomarkör vid screening av preeklampsi : Litteraturfördjupning och verifiering av metodologi

  2016cites this paper
• Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study.

  2016cites this paper
• Facteurs prédictifs et pronostiques de la prééclampsie : intérêt du dosage du PlGF et du sFLT-1

  2016cites this paper
• KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes

  2016cites this paper
• [Predictive and prognostic factors of preeclampsia: Interest of PlGF and sFLT-1].

  2016cites this paper
• Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort

  2016cites this paper
• The association between angiogenic markers and fetal sex: Implications for preeclampsia research.

  2016cites this paper
• Elevated systemic galectin-1 levels characterize HELLP syndrome.

  2016cites this paper
• Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.

  2016cites this paper
• Sflt-1 in heart failure: relation with disease severity and biomarkers

  2016cites this paper
• Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia.

  2015cites this paper